Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Food Effect of KQ-791 in Healthy Subjects
NCT02370043Phase 1Completed
- Sponsor
- Kaneq Bioscience Ltd.
- Start
- Feb 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KQ-791 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Kaneq Bioscience Ltd. Primary endpoint: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug. Started Feb 2015; status: completed.
02
Drugs
KQ-791
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02370043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370043.